StartsidaBIOCON âą NSE
add
Biocon Ltd
FöregÄende stÀngning
364,45Â âč
Dygnsintervall
366,50Â âč - 373,65Â âč
Ă
rsintervall
244,55Â âč - 404,70Â âč
BörsvÀrde
445,69Â md INR
Genomsnittlig volym
5,56Â mn
P/E-tal
55,36
Direktavkastning
0,13Â %
PrimÀr börs
NSE
Aktuellt
Ekonomi
ResultatrÀkning
IntÀkter
Nettoinkomst
(INR) | dec. 2024info | FörÀndring Y/Y |
---|---|---|
IntĂ€kter | 38,56 md | â2,47 % |
Rörliga kostnader | 21,36 md | â3,34 % |
Nettoinkomst | 251,00Â mn | â96,20Â % |
Nettovinstmarginal | 0,65 | â96,11Â % |
Vinst per aktie | 0,13 | â97,54Â % |
EBITDA | 7,42Â md | â5,55Â % |
Giltig skattesats | 47,98Â % | â |
BalansrÀkning
Totala tillgÄngar
Totala ansvarsskyldigheter
(INR) | dec. 2024info | FörÀndring Y/Y |
---|---|---|
Kontanta och kortsiktiga investeringar | â | â |
Totala tillgĂ„ngar | â | â |
Totala ansvarsskyldigheter | â | â |
Totala tillgĂ„ngar | â | â |
UtestĂ„ende aktier | 1,20 md | â |
P/B | â | â |
Avkastning pĂ„ tillgĂ„ngar | â | â |
Avkastning pĂ„ kapital | 2,08 % | â |
Kassaflöde
FörÀndring i nettokassa
(INR) | dec. 2024info | FörÀndring Y/Y |
---|---|---|
Nettoinkomst | 251,00Â mn | â96,20Â % |
Kontanter frĂ„n verksamhet | â | â |
Kontanter frĂ„n investering | â | â |
Kontanter frĂ„n finansiering | â | â |
FörĂ€ndring i nettokassa | â | â |
Fritt kassaflöde | â | â |
Om
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Grundades
1978
Huvudkontor
Hemsida
AnstÀllda
16Â 315